scholarly journals Intrathecal Studies on Animal Pain Models

10.5772/27332 ◽  
2012 ◽  
Author(s):  
Jen-Kun Cheng
Keyword(s):  
Animal Pain ◽  
Pain Models

scholarly journals Analgesic Interaction Between Morphine with Fentanyl In Experimental Murine Pain

2021 ◽  
Author(s):  
Hugo F Miranda ◽  
Viviana Noriega ◽  
Fernando Sierralta ◽  
Ramon Sotomayor-Zarate ◽  
Juan Carlos Prieto
Keyword(s):  
Phase I ◽  
Dose Response ◽  
Multimodal Treatment ◽  
Binding Capacity ◽  
Tail Flick ◽  
Pharmacological Interaction ◽  
Isobolographic Analysis ◽  
Antinociceptive Action ◽  
Animal Pain ◽  
Pain Models

Abstract Opioids are among the most effective pain relievers available, however multimodal antinociception between opioids, has not been extensively studied in diverse animal pain models.In this study the pharmacological interaction of morphine with fentanyl was evaluated in different murine pain models by means of isobolographic analysis. In control animals, morphine and fentanyl produced a dose-related antinociceptive action in the murine assays and the rank of potency was: formalin hind paw phase I > formalin phase II > tail flick. Coadministration of morphine with fentanyl, in a fixed relation 1:1 of their ED50, produces a dose response in all tests and the isobologram resulted in synergism. Fentanyl was more effective than morphine which could be explained according the suggestion that opioids could be acting through other targets, with different binding capacity thru the regulation or activation of non-opioid receptors. Co-administration of morphine with fentanyl induces synergism in all murine trials, confirming the antinociceptive capacity of both opioids which would constitute a promisory idea to multimodal treatment of pain.

Animal pain models

2004 ◽  
Vol 5 (3) ◽  
pp. S17
Author(s):  
V. Smith ◽  
C. Beyer ◽  
M. Brandt
Keyword(s):  
Animal Pain ◽  
Pain Models

Animal pain models

2004 ◽  
Vol 5 (3) ◽  
pp. S17
Author(s):  
P. Robinson ◽  
K. Smith ◽  
A. Loescher ◽  
F. Boissonade ◽  
S. Atkins ◽  
...  
Keyword(s):  
Animal Pain ◽  
Pain Models

230 TAPENTADOL: EFFICACY PROFILE OF A NOVEL CENTRALLY ACTIVE ANALGESIC WITH A DUAL MODE OF ACTION IN ANIMAL PAIN MODELS

2006 ◽  
Vol 10 (S1) ◽  
pp. S62c-S62 ◽  
Author(s):  
J. Vry ◽  
T.M. Tzschentke ◽  
T. Christoph ◽  
M. Méen ◽  
B. Kögel ◽  
...  
Keyword(s):  
Mode Of Action ◽  
Dual Mode ◽  
Animal Pain ◽  
Pain Models ◽  
Efficacy Profile

scholarly journals Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis

2016 ◽  
Vol 8 (4) ◽  
pp. 330-349 ◽  
Author(s):  
Laurent Meijer ◽  
Deborah J. Nelson ◽  
Vladimir Riazanski ◽  
Aida G. Gabdoulkhakova ◽  
Geneviève Hery-Arnaud ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Therapeutic Agent ◽  
Drug Candidate ◽  
Innate And Adaptive Immunity ◽  
Animal Pain ◽  
Pain Models ◽  
Therapeutic Opportunity ◽  
Induction Of Apoptosis ◽  
Preclinical Safety ◽  
Phase I And Ii

(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatment of cancers, Cushing's disease and rheumatoid arthritis. We here review the data that support the investigation of (R)-roscovitine as a potential therapeutic agent for the treatment of cystic fibrosis (CF). (R)-Roscovitine displays four independent properties that may favorably combine against CF: (1) it partially protects F508del-CFTR from proteolytic degradation and favors its trafficking to the plasma membrane; (2) by increasing membrane targeting of the TRPC6 ion channel, it rescues acidification in phagolysosomes of CF alveolar macrophages (which show abnormally high pH) and consequently restores their bactericidal activity; (3) its effects on neutrophils (induction of apoptosis), eosinophils (inhibition of degranulation/induction of apoptosis) and lymphocytes (modification of the Th17/Treg balance in favor of the differentiation of anti-inflammatory lymphocytes and reduced production of various interleukins, notably IL-17A) contribute to the resolution of inflammation and restoration of innate immunity, and (4) roscovitine displays analgesic properties in animal pain models. The fact that (R)-roscovitine has undergone extensive preclinical safety/pharmacology studies, and phase I and II clinical trials in cancer patients, encourages its repurposing as a CF drug candidate.

scholarly journals GABAPENTIN IS EFFECTIVE IN VISCERAL & BIPHASIC ANIMAL PAIN MODELS: AN EXPERIMENTAL STUDY

2015 ◽  
Vol 4 (5) ◽  
pp. 276-279
Author(s):  
Arunim swarup ◽  
Dhanesh Kumar ◽  
Saurabh Kansal ◽  
Priti Sinha
Keyword(s):  
Experimental Study ◽  
Animal Pain ◽  
Pain Models

scholarly journals Pharmacodynamic evaluation of Dezocine injection from Yangtze River Pharmaceutical Group

2021 ◽  
Vol 245 ◽  
pp. 03077
Author(s):  
Rong-Rong Ye ◽  
Yu-Jun Wang ◽  
Xu Xu ◽  
Yan Lu ◽  
Jing-Gen Liu
Keyword(s):  
Molecular Formula ◽  
Analgesic Effects ◽  
Animal Pain ◽  
Pharmaceutical Group ◽  
First Choice ◽  
Pain Models ◽  
First Pass ◽  
Fast Absorption ◽  
Perioperative Pain Management ◽  
Routes Of Drug Administration

Intramuscular injection and intravenous injection are important routes of drug administration, which not only have a fast absorption rate, but also avoid the first pass effect of the drug. In 2009, Yangtze Pharmaceutical Group redeveloped Dezocine(13-Amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-5,11-methanobenzocyclodecen-3-ol), molecular formula: C16H23NO, in the form of njection. Quickly, Dezocine injection becomes the first choice for perioperative pain management in China and accounts for 45 % of the analgesic market. This study mainly used animal pain models to study the analgesic effects of Dezocine injection. The results indicated that Dezocine produced potent analgesic effect in the hot plate and writhing tests.

Translational animal models using veterinary patients – An example of canine osteoarthritis (OA)

2012 ◽  
Vol 3 (2) ◽  
pp. 84-89 ◽  
Author(s):  
Outi Vainio
Keyword(s):  
Chronic Pain ◽  
Animal Models ◽  
Laboratory Animal ◽  
The United States ◽  
Reference List ◽  
Pain Research ◽  
Drug Molecules ◽  
Animal Pain ◽  
Pain Models ◽  
Privately Owned

AbstractBackground and purposeThe use of laboratory animals in pain research has powerfully contributed to our detailed understanding of the physiological mechanisms of pain. Animal models also represent an essential tool to screen and select novel drug molecules with potentially analgesic properties. Despite of the inevitable input of laboratory animal trials, recent studies have shown that animal pain models have repeatedly failed to predict clinical analgesic efficacy and adverse side effects of potential drug molecules in human pain patients. This paper provides a review of the laboratory animal models of OA, which have been developed to test efficacy of novel analgesics. The paper also presents spontaneous OA in canine veterinary patients, and methods to observe chronic pain in nonverbal dogs.MethodsPubMed data base was searched as a reference list to locate most relevant articles. A number of 118 articles including 4 reviews were located. Web pages of 4 establishments and 2 private organizations were also accessed.ResultsThe clinical expression and pathogenesis of naturally occurring OA in dogs is considered an analogous disease that occurs in humans, including pain and lameness. OA may occur in any joint in dogs as well as in humans. Primary idiopathic OA in dogs is rare, but certain breeds may be predisposed to it. For the most part, canine OA is considered secondary to acquired or congenital musculoskeletal disorders. Concomitant factors, such as aging and obesity, likely accelerate progression. However, mechanical factors appear to predominate in the etiopathogenesis of canine spontaneous OA. Both subjective (validated questionnaire) and objective (gait analysis) tools are available to measure OA related pain in dogs. Information on the prevalence of canine OA is limited, but rough surveys suggest that 11 million dogs in the United States and 5 million in Europe could suffer from OA. Ethical considerations concerning the use of privately owned dogs can be resolved by a careful experimental design.ConclusionCanine spontaneous OA could serve as a translational animal model that would more closely mimick clinical OA related pain conditions in humans. Privately owned dogs would make a solution to fix the gap between animal pain models and clinical trials when testing potential analgesic drug molecules. Close interdisciplinary cooperation would guarantee that both scientific and ethical intentions would be achieved.ImplicationsThe predictability of translational pain research would improve by using privately owned dogs as chronic pain models when testing novel analgesics.

Sign in / Sign up

Export Citation Format

Share Document